Bio-Rad Laboratories, Inc. (NYSE:BIO) EVP Michael Crowley sold 700 shares of Bio-Rad Laboratories stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $215.91, for a total transaction of $151,137.00. Following the sale, the executive vice president now owns 2,060 shares of the company’s stock, valued at $444,774.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Bio-Rad Laboratories, Inc. (NYSE BIO) traded up 0.41% on Friday, hitting $215.89. 232,899 shares of the company were exchanged. Bio-Rad Laboratories, Inc. has a 52-week low of $147.68 and a 52-week high of $242.79. The company has a 50-day moving average price of $229.16 and a 200 day moving average price of $212.40. The firm has a market cap of $6.40 billion, a P/E ratio of 426.66 and a beta of 0.91.

WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/bio-rad-laboratories-inc-bio-evp-sells-151137-00-in-stock/1476091.html.

A number of hedge funds have recently modified their holdings of the stock. Canada Pension Plan Investment Board purchased a new stake in shares of Bio-Rad Laboratories during the second quarter valued at about $113,000. Pacad Investment Ltd. purchased a new stake in shares of Bio-Rad Laboratories during the second quarter valued at about $113,000. Advisory Services Network LLC purchased a new stake in shares of Bio-Rad Laboratories during the first quarter valued at about $115,000. Turner Investments LLC purchased a new stake in shares of Bio-Rad Laboratories during the second quarter valued at about $136,000. Finally, Flinton Capital Management LLC increased its stake in shares of Bio-Rad Laboratories by 17.6% in the first quarter. Flinton Capital Management LLC now owns 640 shares of the medical research company’s stock valued at $128,000 after buying an additional 96 shares during the period. 63.73% of the stock is owned by institutional investors.

A number of brokerages have weighed in on BIO. Zacks Investment Research cut shares of Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research report on Thursday. BidaskClub upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. Deutsche Bank AG upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and dropped their price target for the company from $220.00 to $195.00 in a research report on Wednesday, June 28th. TheStreet cut shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $275.00 price target on shares of Bio-Rad Laboratories in a research report on Friday, July 14th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $228.80.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.